MMSI Quote, Financials, Valuation and Earnings

Boston Scientific has a net margin of 8.37% compared to Merit Medical Systems's net margin of 11.12%. Merit Medical Systems's return on equity of 9.56% beat Boston Scientific's return on equity of 8.91%.

Merit Medical Systems has a consensus price target of $113.20, signalling upside risk potential of 16.35%. On the other hand Boston Scientific has an analysts' consensus of $99.14 which suggests that it could grow by 9.36%. Given that Merit Medical Systems has higher upside potential than Boston Scientific, analysts believe Merit Medical Systems is more attractive than Boston Scientific.

Merit Medical Systems has a beta of 0.844, which suggesting that the stock is 15.557% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.802, suggesting its less volatile than the S&P 500 by 19.799%.

Merit Medical Systems has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merit Medical Systems pays -- of its earnings as a dividend. Boston Scientific pays out 1.76% of its earnings as a dividend. Boston Scientific's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Merit Medical Systems quarterly revenues are $339.8M, which are smaller than Boston Scientific quarterly revenues of $4.2B. Merit Medical Systems's net income of $28.4M is lower than Boston Scientific's net income of $468M. Notably, Merit Medical Systems's price-to-earnings ratio is 47.46x while Boston Scientific's PE ratio is 74.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merit Medical Systems is 4.32x versus 8.45x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Globus Medical has a net margin of 8.37% compared to Merit Medical Systems's net margin of 8.28%. Merit Medical Systems's return on equity of 9.56% beat Globus Medical's return on equity of 2.27%.

Merit Medical Systems has a consensus price target of $113.20, signalling upside risk potential of 16.35%. On the other hand Globus Medical has an analysts' consensus of $94.23 which suggests that it could grow by 12.77%. Given that Merit Medical Systems has higher upside potential than Globus Medical, analysts believe Merit Medical Systems is more attractive than Globus Medical.

Merit Medical Systems has a beta of 0.844, which suggesting that the stock is 15.557% less volatile than S&P 500. In comparison Globus Medical has a beta of 1.190, suggesting its more volatile than the S&P 500 by 19.035%.

Merit Medical Systems has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Globus Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merit Medical Systems pays -- of its earnings as a dividend. Globus Medical pays out -- of its earnings as a dividend.

Merit Medical Systems quarterly revenues are $339.8M, which are smaller than Globus Medical quarterly revenues of $625.7M. Merit Medical Systems's net income of $28.4M is lower than Globus Medical's net income of $51.8M. Notably, Merit Medical Systems's price-to-earnings ratio is 47.46x while Globus Medical's PE ratio is 124.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merit Medical Systems is 4.32x versus 4.62x for Globus Medical. Usually stocks with elevated PS ratios are considered overvalued.

ResMed has a net margin of 8.37% compared to Merit Medical Systems's net margin of 25.43%. Merit Medical Systems's return on equity of 9.56% beat ResMed's return on equity of 23.76%.

Merit Medical Systems has a consensus price target of $113.20, signalling upside risk potential of 16.35%. On the other hand ResMed has an analysts' consensus of $256.33 which suggests that it could grow by 9.93%. Given that Merit Medical Systems has higher upside potential than ResMed, analysts believe Merit Medical Systems is more attractive than ResMed.

Merit Medical Systems has a beta of 0.844, which suggesting that the stock is 15.557% less volatile than S&P 500. In comparison ResMed has a beta of 0.684, suggesting its less volatile than the S&P 500 by 31.593%.

Merit Medical Systems has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed offers a yield of 0.87% to investors and pays a quarterly dividend of $0.53 per share. Merit Medical Systems pays -- of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Merit Medical Systems quarterly revenues are $339.8M, which are smaller than ResMed quarterly revenues of $1.2B. Merit Medical Systems's net income of $28.4M is lower than ResMed's net income of $311.4M. Notably, Merit Medical Systems's price-to-earnings ratio is 47.46x while ResMed's PE ratio is 30.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merit Medical Systems is 4.32x versus 7.16x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.

West Pharmaceutical Services has a net margin of 8.37% compared to Merit Medical Systems's net margin of 18.21%. Merit Medical Systems's return on equity of 9.56% beat West Pharmaceutical Services's return on equity of 18.16%.

Merit Medical Systems has a consensus price target of $113.20, signalling upside risk potential of 16.35%. On the other hand West Pharmaceutical Services has an analysts' consensus of $378.17 which suggests that it could grow by 13.49%. Given that Merit Medical Systems has higher upside potential than West Pharmaceutical Services, analysts believe Merit Medical Systems is more attractive than West Pharmaceutical Services.

Merit Medical Systems has a beta of 0.844, which suggesting that the stock is 15.557% less volatile than S&P 500. In comparison West Pharmaceutical Services has a beta of 1.007, suggesting its more volatile than the S&P 500 by 0.671%.

Merit Medical Systems has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. West Pharmaceutical Services offers a yield of 0.24% to investors and pays a quarterly dividend of $0.21 per share. Merit Medical Systems pays -- of its earnings as a dividend. West Pharmaceutical Services pays out 9.61% of its earnings as a dividend. West Pharmaceutical Services's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Merit Medical Systems quarterly revenues are $339.8M, which are smaller than West Pharmaceutical Services quarterly revenues of $746.9M. Merit Medical Systems's net income of $28.4M is lower than West Pharmaceutical Services's net income of $136M. Notably, Merit Medical Systems's price-to-earnings ratio is 47.46x while West Pharmaceutical Services's PE ratio is 49.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merit Medical Systems is 4.32x versus 8.58x for West Pharmaceutical Services. Usually stocks with elevated PS ratios are considered overvalued.